Investors await Sept. 26 FDA decision on zilurgisertib
Incyte’s (INCY) shares rose for the week while Mirum Pharmaceuticals (MIRM) bounced, as investors look ahead to a Sept. 26 FDA decision on zilurgisertib for an ultra-rare bone disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.